191 related articles for article (PubMed ID: 21508122)
1. TET2 mutations in secondary acute myeloid leukemias: a French retrospective study.
Kosmider O; Delabesse E; de Mas VM; Cornillet-Lefebvre P; Blanchet O; Delmer A; Recher C; Raynaud S; Bouscary D; Viguié F; Lacombe C; Bernard OA; Ifrah N; Dreyfus F; Fontenay M;
Haematologica; 2011 Jul; 96(7):1059-63. PubMed ID: 21508122
[TBL] [Abstract][Full Text] [Related]
2. Combined mutations of ASXL1, CBL, FLT3, IDH1, IDH2, JAK2, KRAS, NPM1, NRAS, RUNX1, TET2 and WT1 genes in myelodysplastic syndromes and acute myeloid leukemias.
Rocquain J; Carbuccia N; Trouplin V; Raynaud S; Murati A; Nezri M; Tadrist Z; Olschwang S; Vey N; Birnbaum D; Gelsi-Boyer V; Mozziconacci MJ
BMC Cancer; 2010 Aug; 10():401. PubMed ID: 20678218
[TBL] [Abstract][Full Text] [Related]
3. Internal tandem duplications of the FLT3 and MLL genes are mainly observed in atypical cases of therapy-related acute myeloid leukemia with a normal karyotype and are unrelated to type of previous therapy.
Christiansen DH; Pedersen-Bjergaard J
Leukemia; 2001 Dec; 15(12):1848-51. PubMed ID: 11753604
[TBL] [Abstract][Full Text] [Related]
4. Landscape of TET2 mutations in acute myeloid leukemia.
Weissmann S; Alpermann T; Grossmann V; Kowarsch A; Nadarajah N; Eder C; Dicker F; Fasan A; Haferlach C; Haferlach T; Kern W; Schnittger S; Kohlmann A
Leukemia; 2012 May; 26(5):934-42. PubMed ID: 22116554
[TBL] [Abstract][Full Text] [Related]
5. TET2 mutations improve the new European LeukemiaNet risk classification of acute myeloid leukemia: a Cancer and Leukemia Group B study.
Metzeler KH; Maharry K; Radmacher MD; Mrózek K; Margeson D; Becker H; Curfman J; Holland KB; Schwind S; Whitman SP; Wu YZ; Blum W; Powell BL; Carter TH; Wetzler M; Moore JO; Kolitz JE; Baer MR; Carroll AJ; Larson RA; Caligiuri MA; Marcucci G; Bloomfield CD
J Clin Oncol; 2011 Apr; 29(10):1373-81. PubMed ID: 21343549
[TBL] [Abstract][Full Text] [Related]
6. TET2 mutation is an unfavorable prognostic factor in acute myeloid leukemia patients with intermediate-risk cytogenetics.
Chou WC; Chou SC; Liu CY; Chen CY; Hou HA; Kuo YY; Lee MC; Ko BS; Tang JL; Yao M; Tsay W; Wu SJ; Huang SY; Hsu SC; Chen YC; Chang YC; Kuo YY; Kuo KT; Lee FY; Liu MC; Liu CW; Tseng MH; Huang CF; Tien HF
Blood; 2011 Oct; 118(14):3803-10. PubMed ID: 21828143
[TBL] [Abstract][Full Text] [Related]
7. TET2 mutations in cytogenetically normal acute myeloid leukemia: clinical implications and evolutionary patterns.
Damm F; Markus B; Thol F; Morgan M; Göhring G; Schlegelberger B; Krauter J; Heuser M; Bernard OA; Ganser A
Genes Chromosomes Cancer; 2014 Oct; 53(10):824-32. PubMed ID: 24898826
[TBL] [Abstract][Full Text] [Related]
8.
Pasca S; Jurj A; Tomuleasa C; Zdrenghea M
Medicina (Kaunas); 2020 Nov; 56(12):. PubMed ID: 33255417
[No Abstract] [Full Text] [Related]
9. Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias.
Itzykson R; Kosmider O; Cluzeau T; Mansat-De Mas V; Dreyfus F; Beyne-Rauzy O; Quesnel B; Vey N; Gelsi-Boyer V; Raynaud S; Preudhomme C; Adès L; Fenaux P; Fontenay M;
Leukemia; 2011 Jul; 25(7):1147-52. PubMed ID: 21494260
[TBL] [Abstract][Full Text] [Related]
10. Incidence and prognostic value of TET2 alterations in de novo acute myeloid leukemia achieving complete remission.
Nibourel O; Kosmider O; Cheok M; Boissel N; Renneville A; Philippe N; Dombret H; Dreyfus F; Quesnel B; Geffroy S; Quentin S; Roche-Lestienne C; Cayuela JM; Roumier C; Fenaux P; Vainchenker W; Bernard OA; Soulier J; Fontenay M; Preudhomme C
Blood; 2010 Aug; 116(7):1132-5. PubMed ID: 20489055
[TBL] [Abstract][Full Text] [Related]
11. TET2 expression is a potential prognostic and predictive biomarker in cytogenetically normal acute myeloid leukemia.
Zhang TJ; Zhou JD; Yang DQ; Wang YX; Wen XM; Guo H; Yang L; Lian XY; Lin J; Qian J
J Cell Physiol; 2018 Aug; 233(8):5838-5846. PubMed ID: 29219176
[TBL] [Abstract][Full Text] [Related]
12. Hyperleukocytosis is associated with distinct genetic alterations and is an independent poor-risk factor in de novo acute myeloid leukemia patients.
Tien FM; Hou HA; Tsai CH; Tang JL; Chen CY; Kuo YY; Li CC; Lin CT; Yao M; Huang SY; Ko BS; Hsu SC; Wu SJ; Tsay W; Tseng MH; Liu MC; Liu CW; Lin LI; Chou WC; Tien HF
Eur J Haematol; 2018 Jul; 101(1):86-94. PubMed ID: 29624746
[TBL] [Abstract][Full Text] [Related]
13. [The incidence of TET2 gene mutation and its clinical significance in acute myeloid leukemia patients].
Wei JF; Chen GH; Qiu HY; Fu CC; Ding ZX; Liu H; Feng YF; Chen SN; Chang WR; Wu DP
Zhonghua Xue Ye Xue Za Zhi; 2011 May; 32(5):304-7. PubMed ID: 21729597
[TBL] [Abstract][Full Text] [Related]
14. [FLT3 and NPM1 gene mutations in patients with acute myeloid leukemias and the impact of FLT3-ITD mutations on the survival of patients with a normal karyotype].
Martynkevich IS; Gritsaev SV; Moskalenko MV; Ivanova MP; Aksenova VIu; Tiranova SA; Abdulkadyrov KM
Ter Arkh; 2010; 82(12):33-9. PubMed ID: 21516736
[TBL] [Abstract][Full Text] [Related]
15. [Correlation of NPM1, FLT3-ITD mutations with leukocyte count and myeloblasts percentage in AML patients with normal karyotype].
Su L; Li W; Cui JW; Tan YH; Yang Y; Liu XL; Yu P; Hu RP; Wang LL; Gao SJ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Jun; 21(3):571-5. PubMed ID: 23815900
[TBL] [Abstract][Full Text] [Related]
16. Ten-eleven-translocation 2 (TET2) is downregulated in myelodysplastic syndromes.
Scopim-Ribeiro R; Machado-Neto JA; Campos Pde M; Silva CA; Favaro P; Lorand-Metze I; Costa FF; Saad ST; Traina F
Eur J Haematol; 2015 May; 94(5):413-8. PubMed ID: 25200248
[TBL] [Abstract][Full Text] [Related]
17. TET2 mutations in acute myeloid leukemia (AML): results from a comprehensive genetic and clinical analysis of the AML study group.
Gaidzik VI; Paschka P; Späth D; Habdank M; Köhne CH; Germing U; von Lilienfeld-Toal M; Held G; Horst HA; Haase D; Bentz M; Götze K; Döhner H; Schlenk RF; Bullinger L; Döhner K
J Clin Oncol; 2012 Apr; 30(12):1350-7. PubMed ID: 22430270
[TBL] [Abstract][Full Text] [Related]
18. The prognostic impact of tet oncogene family member 2 mutations in patients with acute myeloid leukemia: a systematic-review and meta-analysis.
Wang R; Gao X; Yu L
BMC Cancer; 2019 Apr; 19(1):389. PubMed ID: 31023266
[TBL] [Abstract][Full Text] [Related]
19. Clinical remission following ascorbate treatment in a case of acute myeloid leukemia with mutations in TET2 and WT1.
Das AB; Kakadia PM; Wojcik D; Pemberton L; Browett PJ; Bohlander SK; Vissers MCM
Blood Cancer J; 2019 Oct; 9(10):82. PubMed ID: 31578317
[No Abstract] [Full Text] [Related]
20. Detection of TET2 Mutation in Patients with De Novo Acute Myeloid Leukemia: A Mutation Analysis of 51 Iranian Patients.
Chehreghani Z; Sadeghian MH; Ayatollahi H; Bagheri P; Zafari Z; Rezazadeh O; Arbab Jafari P
Asian Pac J Cancer Prev; 2022 Mar; 23(3):803-806. PubMed ID: 35345350
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
